U.S. Markets
US FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility
StockNow breaking-news AI analysis
The FDA approved PADCEV plus Keytruda for all MIBC patients, significantly improving survival and pathologic response rates, positioning it as a potential new standard of care for Pfizer, Merck, and Astellas.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.